Pharming Group NV

20-F13G

Schedule 13G - Passive Investments

NASDAQ
PHAR
Pharming Group NV
SCHEDULE 13G/A: Morgan Stanley Reduces Stake in Pharming Group N.V. Below 5% Threshold
Morgan Stanley has filed an amended Schedule 13G, indicating its beneficial ownership in Pharming Group N.V. has decreased to 1.2% as of March 31, 2025, falling below the 5% reporting threshold.